BiotechTube

valdecoxib + diclofenac

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Low Back Pain

Conditions

Low Back Pain

Trial Timeline

Nov 1, 2002 → May 1, 2003

NCT ID
NCT00649610

About valdecoxib + diclofenac

valdecoxib + diclofenac is a approved stage product being developed by Pfizer for Low Back Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT00649610. Target conditions include Low Back Pain.

What happened to similar drugs?

5 of 20 similar drugs in Low Back Pain were approved

Approved (5) Terminated (4) Active (14)
🔄DuloxetineShionogiPhase 3
🔄Duloxetine + PlaceboShionogiPhase 3
🔄Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
🔄EperisoneEisaiPhase 3
🔄Duloxetine + PlaceboEli LillyPhase 3
🔄Duloxetine + PlaceboEli LillyPhase 3
🔄Placebo to Week 16; tanezumab 5mg SC + Placebo to Week 16, tanezumab 10 mg SC + Tanezumab 5 mg SC + Tanezumab 10 mg SC + Tramadol PR oralEli LillyPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00650598ApprovedCompleted
NCT00671320ApprovedCompleted
NCT00649610ApprovedCompleted

Competing Products

20 competing products in Low Back Pain

See all competitors
ProductCompanyStageHype Score
LY3556050 + PlaceboEli LillyPhase 2
35
LY3526318 + PlaceboEli LillyPhase 2
35
DuloxetineShionogiPhase 3
40
Duloxetine + PlaceboShionogiPhase 3
40
Eperisone hydrochloride and Diclofenac sodium + Eperisone hydrochlorideEisaiPhase 3
40
EperisoneEisaiPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
LY3857210 + PlaceboEli LillyPhase 2
35
LY3016859 + PlaceboEli LillyPhase 2
35
Duloxetine + PlaceboEli LillyPhase 3
40
Placebo to Week 16; tanezumab 5mg SC + Placebo to Week 16, tanezumab 10 mg SC + Tanezumab 5 mg SC + Tanezumab 10 mg SC + Tramadol PR oralEli LillyPhase 3
40
Duloxetine + PlaceboEli LillyPhase 3
40
JNJ-42160443 3 mg + JNJ-42160443 1 mg + JNJ-42160443 6 mg/3mg + JNJ-42160443 10 mg + Matching PlaceboJohnson & JohnsonPhase 2
27
tramadol hydrochloride , acetaminophenJohnson & JohnsonApproved
35
tapentadol (CG5503) Immediate Release IR + tapentadol (CG5503) Extended Release (ER) + tapentadol (CG5503) Immediate Release (IR)Johnson & JohnsonPhase 3
40
tapentadol (CG5503) ER + oxycodone CR + placeboJohnson & JohnsonPhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
ABT-712 + PlaceboAbbViePhase 3
40
hydrocodone/acetaminophen extended release + PlaceboAbbViePhase 2
35
AZD1940 + MidazolamAstraZenecaPhase 1
29